Search PubMed⌕ Search

Biomedical subjects

I Romics

Publications and source records attributed to I Romics.

At least 37 records · Page 2Linked to original sources
PubMed1995

[Results of studies of prostate-specific antigen and prostate-specific antigen density in patients with prostatic hypertrophy and prostatic cancer].

The authors investigated the PSA concentration and the preoperative prostate volume of 113 histologically proved BPH and 31 prostate cancer patients. There was no correlation between the age of the patients and the volume of the prostate. Whereas, correlation was proved between the marker concentration and the prostate volume (p < 0.0001). The prostate volume and the PSA concentration ratio correlated between the BPH and tumorous patients (PSA density). The difference was highly significant (p < 0.001). The use of PSAD improves further the diagnostical value of PSA.

Aged↗
PubMed1995

[Flow cytometric examinations of patients after radical surgery for prostatic cancer].

Biological behavior of prostatic cancer is influenced by different tumor factors. The proliferative activity of the malignancies could be one of those parameters which serve as basis to design therapy and to estimate prognosis. Here ploidity and S-phase fraction of 44 prostatic cancer obtained by radical prostatectomy were compared to other known tumor characteristics (PSA, staging, grading). There are correlations between the PSA concentration, grading, staging and S phase fraction. The ploidity correlates with the grading. Neither of kinetic parameter correlated with the nodal involvement.

Aged↗
PubMed1995

[Follow up of patients with prostatic cancer after radical prostatectomy: results, late complication, survival rate].

The authors performed radical prostatectomy on 35 prostate cancer patients between 1986 and 1991. At the end of 1993 the authors were informed about 25 patients. The mean follow-up was 4.4. years. Two patients have died in tumour related diseases, one in intercurrent diseases. In six patients progression was observed. Five patients had to operated because of anastomosis stricture. One patient was operated because of total incontinence another one uses penis clamp.

Anastomosis, Surgical↗
PubMed1995

The prognostic value of prostate specific antigen in the follow-up of patients after radical prostatectomy.

The authors compared the PSA levels in 19 patients who had undergone radical prostatectomy between 1986 and 1991. Measurements were done preoperatively, 3-4 weeks postoperatively and at the end of 1993. The increase of the average preoperative level corresponds to the stage of the disease (local, local advanced, metastatic lymph nodes). Patients with high preoperative PSA levels have a higher risk for progression, even if their postoperative PSA values are normal. While the predictive value of low PSA levels measured immediately after prostatectomy is small, high postoperative PSA levels are unfavourable prognostic signs.

Follow-Up Studies↗
PubMed1994

[Significance of various examination methods in the management of prostatic cancer].

The authors investigated the sensitivity and specificity of four methods: rectal digital examination, prostate specific antigen (PSA), prostatic acid phosphatase (PAP) and transrectal ultrasound in the diagnosis of 100 prostate cancer and 50 suffering in benign prostatic hypertrophy patients. In 21 patients the prostate cancer was proved by perineal punch biopsy and in 79 cases by biopsy and by TUR as well. Because of its simplicity the rectal investigation has to be first one, after that the PSA has to be determined. The specificity of transrectal ultrasound is low. The determination of PAP in addition of PSA is not necessary.

Acid Phosphatase↗
PubMed1994

Preoperative staging and early postoperative complications in radical prostatectomy. Experiences in 35 cases.

It is already a textbook item that in patients with prostatic cancer stage T1-T2 N0M0 radical prostatectomy is the only curative treatment. Radical prostatectomy is indicated also for patients in stage T3 N0M0 who underwent antiandrogenic (Fugerel) treatment for 3 months with the aim of reducing tumour volume. In the following 35 cases will be scrutinized, with special regard to preoperative staging and early postoperative complications.

Humans↗
PubMed1992

[The anti-androgen flutamide in the treatment of prostatic hyperplasia].

The authors treated 23 benign prostatic hyperplasia (BPH) patients with antiandrogen flutamide. Half of the patients were treated with 500 mg, the another part with 750 mg flutamide for three months, and after 3 months brake again for 3 months. The decrease of the residual urine and an increase of the flow were observed. The subjective parameters were improved, too. In some patients side effects (gynecomastia, loss of appetite and potency) were observed. There was no different in the effect of the two doses.

Androgen Antagonists↗
PubMed1992

[5-year experience with BCG immunoprophylaxis in superficial bladder cancer].

Our 5-year experience with BCG in the tumor stage pTis, pTa and pT1, G I-II shows a lasting remission of 88.5% (73%) in 78 (26) patients treated with BCG preparation Pasteur (Connaught) after transurethral resection. A complete remission in patients with carcinoma in situ (12 patients) could be found in 92%. The local and systemic side-effects, which are of limited duration, are tolerable, well treatable and fully reversible.

Antibodies, Neoplasm↗
PubMed1992

[Comparison of the diagnostic value of different tumor markers in prostatic cancer patients].

The author compared the tumour markers of hundred virginell prostatic cancer patients. There were investigated the activity of prostatic acid phosphatase (SP) and its isoenzyme (SPP) by enzymatic method (PAP) as well. The concentration of prostatic specific antigen (PSA) was determined too. The sensibility of markers are growing on the row, SP, SPP, PAP, PSA. Summarising the results, the determination of PAP together with PSA seems to be not necessary. Because of the low price of SP, SPP their determinations is indicated in selected cases. Regarding of costs-benefit the author advises selected investigations in different stage and in different indications.

Acid Phosphatase↗
PubMed1992

Malignant schwannoma of kidney capsule.

This report is of a malignant schwannoma originating in the capsule of the right kidney. Using sonography, nephroangiography, cavography, computer tomography, and bone scanning, metastases in the kidney or a retroperitoneal tumor could be diagnosed. After transperitoneal exploration, the right kidney and mesenteric metastases were removed. Due to tumor infiltration into the liver and tumor masses in the retroperitoneum, only nephrectomy and palliative excision of retroperitoneal metastases were done. Pulmonary metastases developed postoperatively, and the patient died three months after the operation.

Humans↗
PubMed1992

Changes in prostate-specific antigen and prostatic acid phosphatase concentration following prostatic examination in benign prostatic hypertrophy and prostate cancer patients.

The authors measured serum prostate-specific antigen (PSA) and prostatic acid phosphatase concentration in histologically positive prostate hyperplastic and carcinomatous patients before, and 30-60 min and 24 h after prostate manipulation (rectal digital examination, cystoscopy and perineal punch biopsy). After rectal examination, PSA, and after other interventions, both markers changed significantly, although in different points of time and to a different extent. The authors call the attention to the importance of the point of time of the examination. Examination following prostate manipulation may result in wrong diagnosis or in erroneous therapeutic consequences in the follow-up period.

Acid Phosphatase↗
PubMed1992

[Clinical experience with BCG immune prevention in superficial bladder cancer].

Previous randomized studies have shown that in cases of superficial urothelial carcinoma or carcinoma in situ of the urinary bladder, complete and long-lasting remission can be obtained by immunotherapy with bacillus Calmette-Guérin (BCG). Such studies have shown that BCG reduces the recurrence rate significantly compared with transurethral resection alone. Our 6-year experience with BCG Pasteur strain (and Connaught strain, respectively) in tumour stages pTis, pTa and pT1 (G I-II) shows lasting remission in 88.5% (73%) of 78 (26) patients after transurethral resection of the tumour. A complete remission was found in 92% of patients with carcinoma in situ (12 patients). The local and the rare systemic side effects were all of limited duration, tolerable, easily treated and fully reversible.

Administration, Intravesical↗
PubMed1991

Zn, Ca and Na levels in the prostatic secretion of patients with prostatic adenoma.

Zinc, calcium and sodium levels of the prostatic secretions in patients with prostatic adenoma were studied. In a control group of 20 patients, two samples of the secretion, taken on the first and the seventh day, were compared and found to show no difference. In the treated group of 20 patients, where a 7-day therapy of ERU (extractum radix urticae) followed upon the first sampling, the 7th-day specimen presented a significant drop in the Zn level. Correlation was found to exist between the Zn and Ca levels. From literary data the inference was drawn that ERU is producing a derangement in the zinc-testosterone metabolism and diminishes the zinc secretion in adenomatous tissue.

Calcium↗
PubMed1991

Experience with prostate-specific antigen in prostatic carcinoma.

A total of 71 prostatic tumour patients and 45 prostatic adenoma patients were tested for prostate-specific antigen (PSA), immunological prostatic acid phosphatase (PAP) concentration as well as serum prostatic phosphatase (SPP) and enzymic serum phosphatase. It was found among untreated patients that PSA showed the highest percentage of pathologic affection in each stage. PSA, on the evidence of clearance test in the initial days of therapy and after a follow-up period of several months, gave a good picture of the course that the disease had taken.

Acid Phosphatase↗
PubMed1990

[Experience with transrectal ultrasonic studies in patients with prostatic tumors].

The authors present the most typical forms of the prostatic cancer imaged by transrectal ultrasound. They compared the results of investigations of two tumor markers [prostatic specific antigen (PSA), prostatic acid phosphatase (PAP),] the transrectal ultrasound and the rectal palpation. The sensibility of PSA, the ultrasound and the digital investigation were almost the same. The valuability of the transrectal ultrasound investigation in the early diagnosis is limited, but important to determine the stage of the disease, monitoring the process, control of the proper treatment, and in some differential diagnostical problems of the prostate.

Diagnosis, Differential↗